Ultime notizie per Flora Growth (NASDAQ:FLGC) Azioni

Flora Growth

Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company generates revenue from United States, Germany, and the United Kingdom. It derives a majority of its revenue from the United States.

Long Ideas

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

FLGC

TGEN

Martedì l&#39;indice Dow Jones ha chiuso in lieve calo. Quando gli insider acquistano o vendono azioni, questo indica la loro fiducia o preoccupazione per le prospettive dell&#39;azienda. Gli investitori e i trader interessati

Insider trading nelle penny stock: i titoli migliori

Flora Growth Corp

Macro Economic Events

Econ #s

Economics

US Housing Starts (Sep) 1.354M vs 1.35M Est.

USA Housing Starts For September 1.354M Vs 1.350M Est.; 1.361M Prior

WIIM

ALLY

Ally Financial shares are trading lower following Q3 earnings.

American Express Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>)&nbsp;third-quarter revenue (net of interest expense) grew 8% year-on-year to $16.64 billion, marginally missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41399160/american-express-reports-third-quarter-earnings-per-share-of-3-49-and-raises-full-year-2024-eps-gu" rel="noreferrer noopener">analyst consensus estimate of&nbsp;$16.67 billion</a>.&nbsp;
The increase was primarily due to higher net interest income, increased Card Member spending, and continued strong card fee growth.
Amex&#8217;s stock price went up after the report, but it soon gave up the gains in the premarket session on Friday.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41364634/citigroup-remains-a-compelling-investment-opportunity-analysts-take-on-q3-performance" rel="noreferrer noopener">Citigroup Remains A Compelling Investment Opportunity: Analysts Take On Q3 Performance</a>
Adjusted EPS of $3.49 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $3.28</a>.&nbsp;
Card Member spending or Billed Business grew 6% (or 6% forex adjusted) year-over-year to $387.3 billion.&nbsp;
U.S. Consumer Services revenue&nbsp;was $7.944 billion,&nbsp;<a target="_blank" href="https://ir.americanexpress.com/investor-relations/default.aspx" rel="noreferrer noopener">up 10%&nbsp;year over year</a>. Commercial Services revenue was $3.998 billion, up 7%&nbsp;year over year.
International Card Services revenue was $2.936 billion, up 11% year over year, and Global Merchant and Network Services revenue was $1.847 billion, flat year over year.
Total expenses increased by 9%&nbsp;year over year&nbsp;to $12.1 billion, primarily reflecting higher customer engagement costs&nbsp;due to higher Card Member spending, increased usage of travel-related benefits, and higher marketing investments.&nbsp;
Provision for credit losses stood at $1.4 billion, compared with $1.2 billion a year ago, reflecting higher net write-offs.&nbsp;
FY24 Outlook: Amex&nbsp;expects revenue growth&nbsp;of 9% or $65.96 billion (versus <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39857569/american-express-q2-earnings-ceo-raises-annual-profit-and-marketing-spend-outlook-after-q2-profit-b" rel="noreferrer noopener">prior expectations of</a> 9%–11% or $65.96 billion–$67.17 billion) versus&nbsp;consensus of $65.97 billion. It has raised its EPS outlook to $13.75–$14.05 (from $13.30–$13.80 prior) versus&nbsp;the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $13.14</a>.
In August, B of A Securities&nbsp;analyst Kenneth Bruce downgraded&nbsp;American Express, <a target="_blank" href="https://www.benzinga.com/news/24/08/40492134/american-express-faces-growth-challenges-synchrony-and-capital-one-emerge-as-potential-alternatives" rel="noreferrer noopener">citing continued inflation</a> and the higher rate environment affecting consumer demand. He did not expect the company to deliver its previously guided 9%- 11% revenue growth for fiscal 2024.
At least 3 Wall Street firms, including JP Morgan, HSBC, and BTIG, <a target="_blank" href="https://www.benzinga.com/quote/AXP/analyst-ratings" rel="noreferrer noopener">downgraded the stock</a> in October.
American Express stock is up 89% in the last 12 months.
Price Action:&nbsp;AXP stock is down 2.79% at $277.80 premarket&nbsp;at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41389057/solarwinds-plans-riyadh-office-in-2025-citing-growing-tech-investment" target="_blank" rel="noreferrer noopener">SolarWinds Plans Riyadh Office In 2025, Citing Growing Tech Investment</a></li>
</ul>
Photo by DreamerAchieverNoraTarvus via Shutterstock

Earnings

Guidance

Movers

American Express Q3 Earnings: Profit Beats Estimate, Card Spending Grows, Revises Annual Outlook

RBC Capital analyst Brian Abrahams maintains IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) with a Outperform and raises the price target from $17 to $20.

Price Target

Analyst Ratings

IGMS

RBC Capital Maintains Outperform on IGM Biosciences, Raises Price Target to $20

RBC Capital analyst Jon Arfstrom reiterates Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Outperform and maintains $17 price target.

Reiteration

HBAN

RBC Capital Reiterates Outperform on Huntington Bancshares, Maintains $17 Price Target

Procter &amp; Gamble Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) shares are trading lower after the company reported&nbsp;first-quarter&nbsp;sales of&nbsp;$21.74 billion&nbsp;(-1% Y/Y),&nbsp;missing the analyst <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41399117/p-g-announces-fiscal-year-2025-first-quarter-results" rel="noreferrer noopener">consensus estimate of&nbsp;$21.91 billion</a>.
Organic sales, which exclude the impacts of foreign exchange and acquisitions and divestitures, increased&nbsp;by 2%.
Organic sales growth was driven by a 1% increase in higher pricing and a 1% rise in organic volume, excluding the effects of acquisitions and divestitures.
Sales in the Beauty segment fell&nbsp;5%, and the Baby, Feminine &amp; Family Care segment declined 2%.
Meanwhile, the Grooming segment sales sales remained flat, while Fabric &amp; Home Care grew 1% and Health Care sales increased&nbsp;2%.
Gross profit remained flat&nbsp;at $11.3 billion. The reported gross margin expanded by 10 basis points to&nbsp;52.1%, and the core gross margin was flat year-over-year.
Gains included 170 basis points from productivity savings and 30 basis points from pricing, offset by 90 basis points from higher commodity costs, 60 basis points from unfavorable mix, and 40 basis points from product reinvestments.
Operating margin expanded 30 basis points to&nbsp;26.7% while operating income for the quarter rose 1%&nbsp;to&nbsp;$5.80 billion.
Adjusted EPS of&nbsp;$1.93 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the analyst consensus of&nbsp;$1.90.</a>
P&amp;G held&nbsp;$12.16 billion&nbsp;in cash and equivalents as of September 30. Operating cash flow for the quarter was&nbsp;$4.3 billion.
The company returned around $4.4&nbsp;billion&nbsp;of value to shareholders via&nbsp;$2.4 billion&nbsp;in dividend payments and&nbsp;$1.9 billion&nbsp;of share repurchases.
&#8220;We remain committed to our integrated growth strategy of a focused product portfolio of daily use categories where performance drives brand choice, superiority — across product performance, packaging, brand communication, retail execution and consumer and customer value — productivity, constructive disruption and an agile and accountable organization,&#8221; said Board Chairman, President, and CEO Jon Moeller.
Outlook: P&amp;G reaffirmed FY25 guidance for all-in sales growth of&nbsp;2%&nbsp;–&nbsp;4%&nbsp;and <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">organic sales growth of&nbsp;3%&nbsp;–&nbsp;5%</a>.
This&nbsp;outlook equates to FY25 revenue of&nbsp;$85.72 billion&nbsp;–&nbsp;$87.40 billion&nbsp;(versus an estimate of&nbsp;$86.06 billion) and adjusted EPS of&nbsp;$6.91&nbsp;–<a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/40037468/why-gillette-parent-procter-gamble-shares-are-tumbling-today" rel="noreferrer noopener"> $7.05&nbsp;(vs. consensus of $6.97)</a>.
P&amp;G reaffirmed its outlook for adjusted free cash flow productivity of&nbsp;90%, payment of around&nbsp;$10 billion in dividends and repurchasing&nbsp;$6 billion to&nbsp;$7 billion of common shares in fiscal 2025.
Investors can gain exposure to the stock via&nbsp;iShares U.S. Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYK#NYSE">IYK</a>) and Fidelity MSCI COnsumer Staples Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSTA#NYSE">FSTA</a>).
Price Action: PG shares are down 0.81% at $170.88 premarket at the last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41397178/procter-gamble-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earning" target="_blank" rel="noreferrer noopener">Procter &amp; Gamble Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Equities

Large Cap

Dividends

Buybacks

FSTA

iShares Trust Dow Jones USnsumer Goods Sector Index Fund

Procter & Gamble's Mixed Bag Q1: EPS Exceeds Estimates, Reaffirms Growth Outlook & More

Macquarie analyst Tim Nollen maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and maintains $795 price target.

NFLX

Macquarie Maintains Outperform on Netflix, Maintains $795 Price Target

Biotech

General

ARQT

Arcutis Gains Health Canada Approval For ZORYVE Foam 0.3% To Treat Seborrheic Dermatitis In Patients Aged 9 And Older; Marks First New Mechanism Topical Treatment For Condition In Canada In Over 20 Years

Susquehanna analyst Biju Perincheril maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Positive and lowers the price target from $78 to $77.

Susquehanna Maintains Positive on Occidental Petroleum, Lowers Price Target to $77

~10% Shareholder Believes Proposed Sale Represents an Egregious "Take Under" and Significantly Undervalues the Company
Urges the Board to Consider Shareholders' Best Interests and Disclose the Company's 2025 Projections so Investors Can Accurately Value the Company Against the Deal Price
Bradley L. Radoff, who collectively with his affiliates owns approximately 9.9% of the outstanding shares of GSE Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVP#NASDAQ">GVP</a>) ("GSE" or the "Company"), today sent the below letter to GSE Systems' Board of Directors (the "Board") indicating its opposition to the proposed take-private merger with Pelican Energy Partners ("Pelican").
&#x2A;&#x2A;&#x2A;
GSE Systems, Inc. 6940 Columbia Gateway Drive, Suite 470 Columbia, MD 21046 Attention: The Board of Directors
October 18, 2024
Members of the Board,
I am one of GSE's largest shareholders, with an approximately 9.9% stake in the Company. After reviewing the Company's belated and limited disclosures, I believe the proposed sale to Pelican significantly undervalues the Company and puts leadership's interests ahead of shareholders' best interests.
The Board, which collectively has limited public company experience and de minimis share ownership, appears to have allowed the Company to develop liquidity issues that have become the basis for what is seemingly a fire sale. Now, with this deal, the Board is seemingly doubling down on its missteps by giving up on the Company right as the nuclear power industry is entering a renaissance that should be a significant tailwind for GSE and its prospects for enhanced value creation.
Despite GSE's apparent runway for improved financial performance, you have refused to provide a view on the business for 2025. As a result, shareholders are unable to appropriately analyze the Company's prospects and evaluate a standalone future relative to the current deal. The Board's contention that it cannot provide projections because management's forecasts have historically been unreliable simply serves as an acknowledgment of your failures when it comes to governing the business and overseeing the executive leadership you put in place.
With respect to your decision to deprive shareholders of relevant information, it is highly unusual that the Company's definitive proxy statement for the merger did not contain forward-looking business projections. I appear to be one of the many shareholders who are disappointed with this insufficient disclosure. The Company's Form-8-K filed on October 8th, 2024 – just two weeks prior to the shareholder vote – was purportedly only put out in response to "demand letters alleging similar deficiencies and/or omissions regarding the disclosures made in the Preliminary Proxy Statement or the Definitive Proxy Statement."1
In the October 8th 8-K, GSE provided a mere glimpse of very encouraging and positive projections that implied more than $0.30 of quarterly earnings for a Company that currently trades at around $4. The projections, while incomplete, appear to show that the Company is beginning to materially benefit from the nuclear resurgence. Given this context, I am calling on you to provide the market with customary disclosures regarding the Company's forward-looking projections so shareholders can make the most informed decision on the transaction. If the Company continues to provide such limited disclosures as it did in the October 8th 8-K, then it should at least reset the record date for the Pelican merger to enable the investment community to sufficiently digest this new, albeit limited, information.
While the Company's legal counsel and bankers – who stand to make millions if the deal goes through – may have signed off on the disclosures to this point, the Board should know that this deal fails the smell test. Nothing in the merger agreement prevents you from providing more information and transparency to shareholders. I believe your decision to effectively keep GSE shareholders in the dark will define your directorship at GSE and be a black mark for any of you who intend to pursue other director opportunities. Shareholders have long memories.
While you have trumpeted Institutional Shareholder Services' recent report as an endorsement, I don't believe shareholders should give it any credence. The report neglects to mention the lack of initial projections, the magnitude of the late projections and the recent trading activity indicating that shareholders believe there is more value than is being offered by Pelican. In fact, approximately 30% of the Company's outstanding shares have traded at or above the deal price this week.
In closing, I believe an independent GSE has significant upside potential. The Board failed to provide projections prior to the record date and then reluctantly offered limited disclosure just two weeks prior to the shareholder meeting. This set of circumstances, combined with a comical fairness opinion and egregious transaction expenses, are very troubling. I once again demand normal course forward projections so that shareholders, who are the owners of the business, can fairly evaluate the Pelican transaction.
Sincerely,
Bradley L. Radoff

Management

~10% Shareholder Bradley L. Radoff Issues Open Letter To GSE Systems' Board Of Directors To State Opposition To Proposed Sale To Pelican Energy Partners; Believes Proposed Sale Represents An Egregious "Take Under" And Significantly Undervalues The Company

Susquehanna analyst Biju Perincheril maintains Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) with a Neutral and raises the price target from $149 to $154.

Susquehanna Maintains Neutral on Hess, Raises Price Target to $154

Rosenblatt analyst Barton Crockett maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Neutral and raises the price target from $635 to $680.

Rosenblatt Maintains Neutral on Netflix, Raises Price Target to $680

Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZURA#NASDAQ">ZURA</a>) with a Overweight.

ZURA

Cantor Fitzgerald Reiterates Overweight on Zura Bio

As of Oct. 18, 2024, two stocks in the communication services sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">T-Mobile Us Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)</h3>
<ul>
<li>T-Mobile announced redemption of Sprint 7.625% notes due Feb. 15, 2025. The company's stock gained around 13% over the past month and has a <a href="https://www.benzinga.com/quote/TMUS">52-week high of $222.73</a>.</li>
<li>RSI Value: 82.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TMUS Price Action: Shares of T-Mobile Us gained 1% to close at $221.95 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>)</h3>
<ul>
<li>Sify Technologies will announce financial results for the second quarter on Tuesday, Oct. 22. The company's stock gained around 54% over the past month and <a href="https://www.benzinga.com/quote/SIFY">has a 52-week high</a> of $12.30.</li>
<li>RSI Value: 70.98</li>
<li>SIFY Price Action: Shares of Sify rose 14.8% to close at $3.73 on Thursday. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

Short Ideas

SIFY

TMUS

Top 2 Tech And Telecom Stocks That May Crash In Q4

Susquehanna analyst Biju Perincheril maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Positive and lowers the price target from $237 to $233.

FANG

Susquehanna Maintains Positive on Diamondback Energy, Lowers Price Target to $233

One step closer to achieving public reimbursement of AMVUTTRA&#xAE; for hATTR patients in Canada
MISSISSAUGA, ON, Oct. 18, 2024 /CNW/ - Alnylam Canada ULC is pleased to announce that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of AMVUTTRA&#xAE; (vutrisiran injection), an RNAi therapeutic administered by quarterly subcutaneous injection, for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).1&nbsp;This comes following a positive recommendation from the Canadian Drug Agency (CDA) and the Institut national d'excellence en santé et services sociaux (INESSS), and signals the next step in the process where individual participating provinces and territories will start to list&nbsp;AMVUTTRA&#xAE; on their formularies.

Global

ALNY

Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults

Susquehanna analyst Biju Perincheril maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a Positive and lowers the price target from $63 to $62.

Susquehanna Maintains Positive on Devon Energy, Lowers Price Target to $62

Telsey Advisory Group analyst Dana Telsey maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Outperform, adjusts target to $183 from $183 (forward stock split 6:1).

DECK

Telsey Advisory Group Maintains Outperform on Deckers Outdoor, Adjusts Price Target To $183 (forward stock split 6:1)

Susquehanna analyst Biju Perincheril maintains ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) with a Positive and lowers the price target from $147 to $144.

Susquehanna Maintains Positive on ConocoPhillips, Lowers Price Target to $144

Flora Growth reports Q2 results

Warning: FLGC is at high risk of performing badly

Flora Growth (FLGC) just unveiled an announcement. Kevin Taylor stepped down as a director of the company on August 26, 2024, with no disagreements...

Flora Growth Board Changes Ensure Nasdaq Compliance

American views on marijuana effects worsening: Gallup

Flora Growth ( ($FLGC) ) has provided an update. Flora Growth Corp. shareholders have given the green light to significant stock appreciation right...

Flora Growth Approves Stock Rights Plan for Executives

Flora Growth (FLGC) has released an update. Flora Growth Corp. has appointed Harold Wolkin, a finance veteran with over 30 years of experience, to ...

Flora Growth Welcomes New Directors, Aims for Global Expansion

Flora Growth enters supply agreement with Blossom Genetics

Flora Growth (FLGC) has released an update. Flora Growth Corp. has entered a strategic partnership with Blossom Genetics to supply Colombian medica...

Flora Growth Expands into Germany with New Cannabis Strains

Flora Growth signs exclusive distribution agreement with Nordic Tower AB

Flora Growth (FLGC) has released an update. Flora Growth Corp. enhances its German business strategy by appointing Dr. Manfred Ziegler, a seasoned ...

Flora Growth Welcomes New Director to Expand in Europe

AAWH

AYRWF

CNBS

CRLBF

CRON

CURLF

CWBHF

ETRGF

GLASF

GTBIF

HITI

JUSHF

MAPS

MRMD

PCLOF

PLNH

SNDL

TCNNF

TLRY

VRNOF

YCBD

YOLO

Health Care

Press Releases

Lifeist Terminates Agreement for Sale of Australian Vapes

Opinion

Thinking about buying stock in Mullen Automotive, Lucid Group, Lithium Americas, Tigo Energy, or Flora Growth?

Flora Growth Corp's CEO Reveals Record-Breaking Financials and Exciting 2024 Plans

Thinking about buying stock in Entera Bio, Ocugen, Mind Medicine, MicroAlgo, or Flora Growth?

Aegis Capital Corp. Acted as Sole Bookrunner on a $3.23 Million Underwritten Public Offering for Flora Growth Corp. (NASDAQ:FLGC)

Vessel Brand Unveils the Second-Generation Compass Rise - The Next Evolution in Functionality and Elegance

Flora Growth Corp. Forms Joint Venture with Althea Group Holdings to Create Leading Beverages Brand in U.S. Market

Comments

Flora Growth

Notizie

Ultime notizie per Flora Growth (NASDAQ:FLGC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO